Oncology

Functional MRI biomarkers supporting oncology trials, including diffusion, DCE-MRI, and hypoxia imaging.

Tumour hypoxia imaging map — Oxygen-enhanced MRI can map tumour hypoxia and therapy response.

Bioxydyn provides advanced functional MRI biomarkers in oncology, using techniques such as diffusion MRI and dynamic contrast-enhanced (DCE) MRI. We are a leading CRO offering tumour hypoxia imaging to inform therapy effectiveness and characterise tumour physiology.

We are world-leading in the use of oxygen-enhanced MRI (OE-MRI), which can be applied to monitor the delivery of oxygen to tumours. Tumour oxygenation levels impact disease progression and response to therapy, and our methods for identifying hypoxia are sensitive to drug and radiotherapy effects.

Parametric tumour hypoxia map — Parametric hypoxia maps derived from OE-MRI (example).

Dynamic contrast-enhanced MRI is recognised by the Quantitative Imaging Biomarkers Alliance (QIBA) as a biomarker of angiogenesis and vascular function in cancer. Bioxydyn personnel bring decades of experience to the study of cancer using DCE-MRI.

Diffusion MRI, using the apparent diffusion coefficient (ADC), detects changes in water diffusion and can act as an early marker of biological response to treatment. These measurements support sensitive, repeatable imaging endpoints in oncology trials.